Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
吉利德科学表示，大多数进行第3期原发性胆汁性胆管炎患者使用Livdelzi治疗后实现了生化学反应
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间